Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life

Agirrezabal, Ion; Brennan, Victoria K; Colaone, Fabien; Shergill, Suki; Pereira, Héléna; Châtellier, Gilles; Vilgrain, Valérie

doi:10.1007/s12325-022-02099-0

Cited by 10 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further multivariate regression analysis has elucidated pivotal factors influencing fatigue in liver cancer patients post-TAE, including marital status, presence of family members, and age[ 17 , 18 ]. Consistent with prior research, our study reveals that younger patients are more susceptible to experiencing fatigue.…”

Section: Discussionmentioning

confidence: 99%

Influence of transcatheter arterial embolization on symptom distress and fatigue in liver cancer patients

Yang,

Wang

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND Hepatocellular carcinoma (HCC) is a prevalent malignancy, and transcatheter arterial embolization (TAE) has emerged as a pivotal therapeutic modality. However, TAE may induce symptom distress and fatigue, adversely affecting the quality of life of patients. AIM To investigate symptom distress, fatigue, and associated factors in HCC patients undergoing TAE. METHODS We used a cross-sectional design and purposive sampling to enroll HCC patients who underwent TAE at our institution from January to December 2022. Questionnaires were utilized to collect data on symptom distress and fatigue scores from the first to the third day after TAE. RESULTS Our study revealed a significant reduction in fatigue and symptom distress among patients after TAE. Pain, fatigue, insomnia, fever and abdominal distension were the most common symptoms troubling patients during the first 3 d post-TAE. Marital status, presence of family support, physical functional status, age, and symptom distress were identified as predictors of fatigue in patients. CONCLUSION Healthcare professionals should educate HCC patients on symptom distress and fatigue, offering personalized relief strategies to lessen their psychological burden.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of transcatheter arterial embolization on symptom distress and fatigue in liver cancer patients

Yang,

Wang

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Compared to sorafenib, better tolerability has also been reported for TARE with fewer adverse events and a higher quality of life [11,12]. In fact, recently, an indirect comparison between patients in the SARAH and IMbrave150 trial has shown similar time to deterioration of quality of life [18]. With reports showing a similar safety profile, we aimed to identify patients who would benefit from TARE or atezolizumab/bevacizumab and improve individual treatment allocation.…”

Section: Discussionmentioning

confidence: 99%

Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab

Jeschke,

Ludwig,

Leyh

et al. 2023

Cancers

View full text Add to dashboard Cite

Recommended treatment options for advanced-stage hepatocellular carcinoma (HCC) include systemic therapy (ST) and trans-arterial radioembolization (TARE) with Yttrium-90 (Y90). Before the approval of immune-checkpoint inhibitors, a similar safety profile was reported for TARE and ST with tyrosine kinase inhibitors (TKI). However, whole-liver treatment and underlying cirrhosis were identified as risk factors for potentially lethal radioembolization-induced liver disease (REILD). Therefore, the safety and efficacy of TARE and ST with atezolizumab/bevacizumab were compared in patients with advanced HCC involving at least both liver lobes in a retrospective real-world cohort. In total, 74 patients with new or recurrent advanced-stage HCC (BCLC stage B/C) were included if treated with either bilobar TARE (n = 33) or systemic combination therapy with atezolizumab plus bevacizumab (n = 41). Most patients had compensated liver function (90.5% were classified as Child-Pugh Score A, 73% as ALBI Grade 1) at baseline. Although not significant, patients treated with ST showed a more prolonged overall survival than those treated with Y90 TARE (7.1 months vs. 13.0 months, p = 0.07). While a similar disease control rate could be achieved with bilobar TARE and atezolizumab/bevacizumab, in the TARE group, overall survival was curtailed by the occurrence of REILD. In patients with underlying liver cirrhosis, the liver function at baseline was a predictor for REILD.

show abstract

“…Endothelial cells play a critical role in regulating cardiovascular functions, as they are ubiquitously found in the lining of blood vessels. Endothelial cell dysfunction after TBI leads to dysregulation of the cardiovascular system, manifesting as volatile blood pressure, electrocardiogram changes, arrhythmias, and poor cardiac function (52)(53)(54)(55)(56)(57)(58)(59).…”

Section: Cardiovascularmentioning

confidence: 99%

The neuro-endothelial axis in traumatic brain injury: mechanisms of multi-organ dysfunction, novel therapies, and future directions

Ho,

Dawood,

Taylor

et al. 2024

Shock

View full text Add to dashboard Cite

Severe traumatic brain injury (TBI) often initiates a systemic inflammatory response syndrome (SIRS), which can potentially culminate into multi-organ dysfunction (MOD). A central player in this cascade is endotheliopathy, caused by perturbations in homeostatic mechanisms governed by endothelial cells due to injury-induced coagulopathy, heightened sympathoadrenal response, complement activation, and pro-inflammatory cytokine release. Unique to TBI is the potential disruption of the blood-brain barrier (BBB), which may expose neuronal antigens to the peripheral immune system and permit neuroinflammatory mediators to enter systemic circulation, propagating endotheliopathy systemically. This review aims to provide comprehensive insights into the “neuro-endothelial axis” underlying endothelial dysfunction following TBI, identify potential diagnostic and prognostic biomarkers, and explore therapeutic strategies targeting these interactions, with the ultimate goal of improving patient outcomes following severe TBI.

show abstract

Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life

Cited by 10 publications

References 39 publications

Influence of transcatheter arterial embolization on symptom distress and fatigue in liver cancer patients

Influence of transcatheter arterial embolization on symptom distress and fatigue in liver cancer patients

Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab

The neuro-endothelial axis in traumatic brain injury: mechanisms of multi-organ dysfunction, novel therapies, and future directions

Contact Info

Product

Resources

About